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Abstract
Background: It has been verified that taurine has some preventive effects on diabetes and its complications when
used alone or together with other drugs, but there are few reports about taurine on the prevention of diabetic
nephropathy, the mechanisms of which are still unknown.
Methods: Taurine was administered to type Ⅱ diabetic rats induced by high fat high sugar diet combined with
STZ injection. The preventive effect of taurine on diabetic nephropathy was investigated by detecting blood
glucose, lipid metabolism, kidney function and glomerular basement membrane metabolism.
Results: Taurine could lower blood glucose, TG, TC, BUN, Scr, NAG, U-PRO, the expression of laminin B1( LBN1)
mRNA, and increase HDL-C of diabetic rats.
Conclusions: The results indicated that taurine could prevent the occurrence and development of diabetic
nephropathy by decreasing blood glucose, improving lipid metabolism, glomerular basement membrane
metabolism, and kidney function.
Introduction
Diabetic nephropathy (DN) whose incidence is up to
47.66% is the most common and difficult diabetic
microvascular complication to treat and has become the
first cause of end-stage renal disease [1-3]. It is reported
that about 43% of the chronic renal failure (CRF)
patients on dialysis are DN, 60% case fatality of diabetes
mellitus (DM) patients are DN, DM patients who died
of renal failure are 17 times more than non-DM patients
[4]. Therefore, prevention of the occurrence and the
development of DN has become a very urgent issue.
Taurine, a sulfur-containing b-amino acid with a wide
range of biological effects, is the most abundant free
intracellular amino acid presents in many tissues of
humans and animals [5]. Researches have demonstrated
that taurine has some preventive and curative effects on
DN. H.Trachtman (1995) found that 1% taurine
supplementation in drinking water for 52 weeks could
reduce total proteinuria (U-PRO) and albuminuria by
nearly 50%. This treatment also prevented glomerular
hypertrophy, diminished glomerulosclerosis and tubu-
lointerstitial fibrosis in diabetic animals [6]. It was
reported by A.Erden (2000) that taurine could reduce
gentamicin induced increases in serum creatinine (Scr),
24h urine volume, serum urea nitrogen (BUN) and tis-
sue lactate and TBARS levels [7]. S.Higo (2008) reported
that taurine administration significantly suppressed
further increase in urinary protein excretion in diabetic
rats [8]. Four weeks after intravenous injection of 50
mg/kg streptozotocin (STZ), diabetic rats exhibited 6.1
fold increase in urinary protein excretion, taurine sup-
plement by 1% in drinking water prevented increases
proteinuria [9].The reports mentioned above indicated
that the previous study about taurine on DN were all
concerned with typeⅠDN induced by STZ. There were
no reports about preventive effects of taurine on type Ⅱ
DN by artificial induction. In diabetes mellitus, expan-
sion of the glomerular mesangium correlates with the
clinical features of diabetic kidney disease. The increase
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tion of normal matrix proteins, including collagens type
IV and type V, laminin (LN), and fibronectin [10]. As a
main protein composition in glomerular basement
membrane, LN could reflect the dynamic state of extra-
cellular matrix (ECM) synthesis. So LN was considered
as a main index for renal injury, as well as for the devel-
opment of DN. There were no reports about the effect
of taurine on LN.
In this study, the preventive effect and its mechanism
of taurine on DN would be investigated, in order to pro-
vide a theoretical basis for clinical application of taurine.
Methods
Experimental animals and treatments
Six-week-old male Wistar rats weighing 140-180g were
maintained under a controlled condition of light (12h of
light,12h of dark) and temperature (23±2℃), and were
given free access to food (commercial standard rat
chow) and water.
One hundred and ten male Wistar rats weighing 140-
180g were randomly divided into two groups: normal
control group (A group, 20 rats) and model group (M
group, 90 rats). Rats in M group were fed with a high
sugar, high fat diet for one month to induce insulin
resistance (IR), and then injected with STZ (25mg/kg)
once per week for two weeks. Rats in A group were
injected with citric acid-citrate sodiumb u f f e rs o l u t i o n .
Rats in M group were fed with a high sugar, high fat
diet for two months after STZ injection. Then fasting
blood glucose, random blood glucose and fasting insulin
were detected seven days after the second STZ injection.
DM rats in M group were divided into four groups ran-
domly (18 rats in each group): spontaneous recovery
group (B), high concentration of taurine group (C),
medium concentration of taurine group (D) and low
concentration of taurine group (E). Rats in B, C, D and
E groups were administered with 0mg/kg, 3.4mg/kg,
2.6mg/kg, and 2.1mg/kg 70% taurine suspension respec-
tively. Rats in A and B groups received the same treat-
ment. At the end of the 6th and the 10th weeks, five
rats were selected from each group, blood was collected
from the jugular vein, then BUN, Scr, b-N-acetyl-gluco-
saminidase (NAG), triglyceride (TG), total cholesterol
(TC) and high-density lipoprotein cholesterol (HDL-C)
were detected. Twenty-four h urine samples were col-
lected and U-PRO was detected. Renal basement mem-
brane adhesion protein expression was detected by way
of in-situ hybridization.
Chemicals
Blood glucose meters and blood glucose test strips with
lot number were purchased from U.S. Roche. STZ was
purchased from Sigma Chemical Company. Sugar,
cholesterol, and bile salt were purchased from Shenyang
Chemical Reagent Co., Ltd. Taurine was purchased from
Beijing Capital Commercial Source Co., Ltd. Insulin RIA
kit was purchased from China Institute of Atomic
Energy Research Institute of Isotopes. BUN, Scr, NAG,
U-PRO, TG, TC, HDL-C kits were purchased from
Nanjing Jiancheng Bioengineering Institute. Diethyl pyr-
ocarbonate (DEPC), Paraformaldehyde, Special coverslip
in situ hybridization and in situ hybridization detection
kits were purchased from Wuhan Boster Biological
Engineering Co., Ltd.
Experimental diets
Normal diet was purchased from Yuhong District test
animal feed factory (Shenyang), the nutrition ingredient
of which is in accordance with the nutritional standards.
High-fat high-sugar feed was purchased from Yuhong
District test animal feed factory (Shenyang) which con-
tains 15% lard, 25% sucrose, 2.5% cholesterol, 1% bile
salts and 56.5% normal feed.
Judgments of model
Determination of fasting blood glucose: After an over-
night (10–12 h) fast, during which only water was per-
mitted. Blood was collected from the tail. The first drop
of blood was wiped off, and the second drop of blood
was used to determine the blood glucose using blood
glucose test strips.
Determination of random blood glucose: without fast-
ing, methods were the same as mentioned above. Deter-
mination of insulin levels: 200-300μL whole blood was
collected from the tails. After standing at room tem-
perature for 4h, serum was separated by centrifuging at
1500 rpm for 15 min at 4℃. INS was determined using
an insulin RIA kit.
The establishment of animal models of T2DM must
meet the following two conditions:
(1) ISI = Ln [1 / (fasting glucose × serum insulin
level)] ≤the mean value of normal animals;
(2) the mean value of random blood glucose levels in
normal rats +2 standard deviation ≤ the random blood
glucose of model group.
Standardization of insulin resistance
HOMA-IR=(FBGxFINS)／22.5 was used to evaluate the
degree of insulin resistance, while ISI=1／(FBGxFINS)
was used to demonstrate the insulin sensitivity. Calcu-
late the natural logarithm of HOMA-IR and ISI [11].
Biochemical analysis
Blood samples were collected from the jugular vein of 5
rats randomly selected from each group at the end of
the 6th and the 10th weeks. After standing at room
temperature for 4h, serum was separated by centrifuging
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Scr, NAG, TG, TC, HDL-C were determined by colori-
metry using kits. U-PRO was detected using urine col-
lected from a metabolic cage for 24 hours.
Kidney in-situ hybridization
The paraffin section of the rat’s kidney was dewaxed.
Endogenous peroxidase was deactivated after being trea-
ted with 3% hydrogen peroxide at room temperature for
10 min. Then the section was digested with pepsin at
37 ℃ for 20 min in order to expose the mRNA nucleic
acid fragment. Dropped 20μl oligonucleotide probe
hybridization solution containing Cardiox was added on
each slice over night. Then confining liquid, biotinyla-
tion rat anti biotinylation antibody and SABC were
added to each section. They were then colored with
DAB, redyed with hematoxylin, transparented with
xylene, and mounted with neutral gum. The assessment
criteria of positive cells: the cell is positive if there are
brown granules in the cytoplasm observed under optical
microscope. Negative control of in situ hybridization:
0.5mol/LPBS was used instead of nucleotide probe
hybridization solution, repeat the above steps. The
expression value was measured using the average rela-
tive gray scale.
Statistical analysis
Data were presented as the mean ± SD and significant
differences were determined by Duncan’s multiple range
tests using SPSS 16.0 statistical analysis software. P values
less than 0.05 were considered as significant, P values less
than 0.01 were considered as extremely significant.
Results
Percentage of model establishment
Random blood glucose and ISI of groups A and M were
shown in Table 1. The result meets the requirements of
the T2DM rat model. 74 rat models were established,
the percentage was 82%.
Insulin resistance analysis
FBG, FINS, ISI and HOMA-IR of groups A and M were
shown in Table 2.The FBG and HOMA-IR of Group M
was significantly higher (P ＜0.01) than the normal rats
at the seventh day after STZ injection. The FINS and
ISI of Group M was significantly higher (P ＜0.05) than
the normal rats. The results indicated that 74 rats in the
model group all exhibited insulin resistance, which
means that the rats were type Ⅱ diabetes models.
Blood glucose analysis
Figure 1 showed that the blood glucose level of sponta-
neous recovery group was significantly higher (P ＜0.01)
than the normal rats at the end of the 6th and the 10th
weeks. The blood glucose level of the taurine- preven-
tive groups was significantly lower than that of the
spontaneous recovery group, and particularly the high-
concentration of taurine group had no significant differ-
ences compared with the control group.
Analysis of lipid metabolism indexes
As shown in Fig. 2, serum concentrations of HDL-C,
TG and TC in the spontaneous recovery group were
significantly affected compared with the control group
(P＜0.01 or P＜0.05), among which, the concentration
of HDL-C was significantly decreased, and the concen-
trations of TG and TC were significantly increased.
Table 1 Results of the random glucose level and ISI of
Group C and M
Group amount random blood glucose (mmol/
L)
ISI
Model group 74 15.03±9.53 -5.13
±0.69
Control
group
20 6.3±0.46 -4.32
±0.46
Results are presented as mean±SD C: control group, M: model group
Table 1 The results of the level of random glucose and ISI of Group A and M
Table 2 Results of the insulin resistance of Group C
and M
Group amount FBG (mmol/
L)
FINS(IU/L) ISI HOMA-
IR
Model
group
74 5.43±0.75
** 34.59
±13.86
*
-5.13
±0.69
*
2.04
±0.40
**
Control
group
20 4.02±0.29 21.45±5.33 -4.32
±0.46
1.36±0.26
Results are presented as mean±SD C: control group, M: model group
Table 2 The results of the insulin resistence of Group A and M
*P ＜0.05
**P＜0.01
Figure 1 Levels of GLU in each group at the 6th and the 10th
weekends. Results are presented as mean±SD (n=5). *: significantly
different from control group (p<0.05), **: extremely significantly
different from control group (p<0.01).
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ciated with lipid metabolism nearly to the normal levels.
Analysis of kidney functional parameter
As shown in Fig. 3, the concentrations of BUN, Scr and
N A Gw e r es i g n i f i c a n t l yh i g h e ri nt h es p o n t a n e o u s
recovery group compared with the control group, while
there were no significant differences between the taurine
and the control groups. At the end of the 10th week, the
concentration of NAG in the high concentration of tau-
tine group was significantly lower than that of the con-
trol group, while the concentration of which was
significantly higher than the control group.
Expression of kidney basement membrane adherent
protein
As shown in Fig. 4, the expression level of LNB1mRNA
in the spontaneous recovery group was extremely signif-
icantly higher than the control group (P<0.01). At the
end of the 6th week, the expression levels in the low
and medium concentration of taurine groups were sig-
nificantly higher than the control group (P<0.05), while
which in the high concentration of taurine group was
significantly lower than the control group (P<0.05). At
the 10th weekend, the expression levels in the medium
and the low concentration of taurine groups were extre-
mely significant higher than the control group (P<0.01),
while the high concentration of taurine group had no
significant differences compared with the control group.
It was shown in Fig. 5 that at the end of the 6th and
the 10th weeks, the expression level of LNB1mRNA in
the spontaneous recovery group was significantly higher
than the control group. At the end of the 6th week, the
expression level in the high concentration of taurine
group was significantly lower than the control group.At
the end of the 10th week, the expression level in the
high dose of taurine group had no significant differences
compared with the control group, meanwhile it was
lower than the spontaneous recovery group at the end
of the 6th and the 10th weeks.
Discussion
Blood glucose level and DN
In 1993, a report from American Diabetes Academy and
the diabetes control and complications trial（DCCT）
published in the New England Medical Journal verified
that intensification therapy of insulin could keep the blood
glucose at normal level and postpone the occurrence and
the development of DN [12]. In addition, a perspective
study in England verified that intensification therapy of
insulin could obviously decrease the occurrence of type Ⅱ
DN [13]. These clinical researchers demonstrated the
effect of high glucose in the occurrence and the develop-
ment of DN. It has been reported that taurine
Figure 2 Levels of lipid metabolism indexes in each group. a:
The level of HDL-C, b: The level of TG, c: The level of TC,. Results
are presented as mean±SD (n=5). *: significantly different from
control group (p<0.05), **: extremely significantly different from
control group (p<0.01).
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could not only decrease the high blood glucose level, but
also inhibit the decrease of serum insulin [14]. Harold OG
et al and Donadio et al found that taurine preventively
given to STZ induced insulin-dependent DM animal mod-
els could significantly decrease blood glucose, increase glu-
cose content in skeletal and cardiac muscles, facilitate the
composition and degradation of glycogen, and promote
the transformation from 3H-glucose to glycogen [15,16].
But Ha et al (1999) believed that taurine could not
decrease blood glucose. This study confirmed that taurine
could effectively reduce blood glucose, prevent the occur-
rence and development of DN, which is consistent with
most reports.
Lipid metabolism and DN
Clinical research found that lipid metabolism disorder is
an independent risk factor of type ⅡDN. It has been con-
firmed by animal experiment that hypercholesteremia
could cause focal glomerulosclerosis. Kasiske et al. have
reported that hypertriglyceridemia accelerated the occur-
rence of albuminuria and glomcrulus damage in obesity
model rats [17]. The increase of blood is equal to the
increase of urinary albumin excretion rate. The decrease
of the blood fat could protect the kidney from glomerular
sclerosis.
HDL-C is a protective factor against atherosclerosis. It
can prevent the occurrence of renal artery atherosclero-
sis, reducing the probability of DN. Lin (1998) and Zhao
(2005) confirmed that taurine could decrease serum TG,
TC, increase HDL-C level of rats fed with high fat diet,
which means that taurine could improve lipid metabo-
lism of rats fed with high fat diet [18,19]. Nishimura
investigated rats with genetic type ⅡDM and found that
taurine could obviously decrease plasma TC in rats fed
with high cholesterol diet. While taurine had no effect
on plasma TC in rats fed with normal diet, but could
significantly increase plasma HDL-C in GK rats. These
results indicated that taurine had a significant effect on
decreasing blood fat and promoting lipid metabolism.
Figure 3 Levels of kidney functional parameter. a: The level of BUN, b: The level of NAG, c: The level of Scr, d: The level of U-PRO. Results are
presented as mean±SD (n=5). *: significantly different from control group (p<0.05), **: extremely significantly different from control group
(p<0.01).
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and found that taurine could obviously decrease plasma
TC and increase plasma HDL-C in rats [20]. This study
showed that taurine could increase HDL-C, decrease TC
and TG, which confirmed that taurine can reduce the
probability of DN by effectively improving lipid
metabolism.
Basement membrane adherent protein expression and
DN
The main pathological changes of DN is the thickening
of the glomerular capillary basement membrane, the
proliferation of mesangial cells and the increase of
mesangial matrix, the thickening of tubular basement
membrane, and eventually leading to diffuse or nodular
glomerulosclerosis, and tubulointerstitial interstitial
fibrosis. LN which located inside the loose layer of
GBM, is an important constitution of GBM and ECM.
LN plays important roles in mediating the interaction
between the cells and matrix, cell adhesion, migration,
proliferation and differentiation. LN can cause cell adhe-
sion and affect the selectivity of GBM charge. As a sign
of kidney damage, LN is an important index for DN
development [21]. Immunohistochemically an increase
Figure 4 Levels of kidney basement membrane adherent
protein expression. A: LNB1mRNA expression level of the control
group At the end of the 6th and the 10th weeks, B: LNB1mRNA
expression level of the spontaneous recovery group At the end of
the 6th and the 10th weeks, C:LNB1mRNA expression level of high
concentration of taurine group At the end of the 6th and the 10th
weeks, D: LNB1mRNA expression level of the medium concentration
of taurine group At the end of the 6th and the 10th weeks, E:
LNB1mRNA expression level of the low concentration of taurine
group At the end of the 6th and the 10th weeks. Results are
presented as mean±SD (n=4). *: significantly different from control
group (p<0.05), **: extremely significantly different from control
group (p<0.01).
Figure 5 In situ hybridization of adherent protein expression in kidney basement membrane. The brown area was the positive
expression area, enlarge 400ⅹ under light microscope. a: LNB1mRNA expression level of the control group at the end of the 6
th week，b:
LNB1mRNA expression level of the spontaneous recovery group at the end of the 6
th week，c: LNB1mRNA expression level of the high
concentration of taurine group at the end of the 6
th week， d: LNB1mRNA expression level of the control group at the end of the 10
th week，e：
LNB1mRNA expression level of the spontaneous recovery group at the end of the 10
th week，f: LNB1mRNA expression level of the high
concentration of taurine group at the end of the 10
th week.
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mesangium and in the glomerular basement membrane
[22]. The first laminin was isolated in 1979 from the
mouse Engelbreth–Holm–Swarm (EHS) tumour [23].
LN is a large basement membrane-specific glycoprotein
composed of three chains:A,B1,B2 [24]. Structural analy-
sis using electron microscopy revealed LN as a cruci-
form-like structure with three short arms and one long
arm [25]. The long arm consists of an a-helical coiled
coil and is the only region in which all three chains
associate [26]. In fact, in the absence of collagen IV, the
other major component that assembles into a scaffold,
LN has been shown to be sufficient for forming base-
ment membrane-like matrices during early development
of mice embryos [27]. Immunostaining for laminin
w a si n c r e a s e di nt h ed i a b e t i cm a l eS Dr a t s( 2 0 0 –250g)
by intravenous injection of STZ in citrate buffer
(50 mg/kg) as compared with the control group [28].
Light and electron microscopy demonstrated a moderate
increase of mesangial matrix and thickening of the glo-
merular basement membrane in diabetic rats. Fukui et
al. reported increased mRNA levels for a1(IV) collagen,
LNB1 and B2, and a1(I) and a1(III) collagen in diabetic
rats 4 wk after STZ before morphological thickening of
basement membrane occurred [29]. LNB1 mRNA level
was increased 1.7 fold in diabetic NOD mice than in
agematched nondiabetic NOD mice with normal glucose
tolerance [30]. In this experiment, LNB1 cDNA probes
were used for in situ hybridization, which can efficiently
detect the LN level in glomerular basement membrane.
This study confirmed that high doses of taurine can
effectively reduce the expression level of LNB1mRNA
and improve the metabolism of glomerular basement
membrane. However, this improvement was reduced
with time, the specific mechanism of which remains to
be further investigated.
Conclusion
In conclusion, taurine has some preventive effect on
experimental type Ⅱ DN, the mechanism of which may
be due to the decreasing blood glucose , improving lipid
metabolism, glomerular basement membrane metabo-
lism, and kidney function.
List of abbreviations used
DM: diabetes mellitus; DN: diabetic nephropathy; HDL-C: high-density
lipoprotein cholesterol; TG: triglyceride; TC: total cholesterol; BUN: blood urea
nitrogen; Scr: proteinuria; STZ: streptozotocin; DEPC: diethyl pyrocarbonate;
ECM: extracellular matrix ; CRF: chronic renal failure; LN: laminin; LNB1:
laminin B1; GBM: glomerular basement membrane; FBG: fasting blood
glucose; FINS: fasting insulin; ISI: insulin sensitivity index; HOMA-IR:
homeoestasis model assessment -insulin resistance.
Acknowledgements
This article has been published as part of Journal of Biomedical Science
Volume 17 Supplement 1, 2010: Proceedings of the 17th International
Meeting of Taurine. The full contents of the supplement are available online
at http://www.jbiomedsci.com/supplements/17/S1.
This work was supported by the National Natural Science Foundation of
China (Grant No. 30972154) and Talents Project of Liaoning Provincial
Department of Education (Grant No.2009R50).
Authors’ contributions
Shumei Lin carried out determination of blood glucose targets, participated
in the study design and drafted the manuscript. Jiancheng Yang participated
in the detection of insulin resistance, the design of the study and performed
the statistical analysis. Gaofeng Wu carried out the Sampling and insulin
determination. Mei Liu participated in detection of lipid metabolism.
Xinhong Luan participated in detection of LNB1 in situ hybridization in
kidney. Qiufeng Lv participated in rat raising. He Zhao carried out the
establishment of type Ⅱ diabetes model. Jianmin Hu conceived of the study,
and participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Published: 24 August 2010
References
1. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T:
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An
epidemiological study. Diabetologia 1983, 25(6):496-501.
2. Mats B, Hans JA, Goran H, Bengt EK, Johnny L: Declining Incidence of
Nephropathy in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1994,
330(1):15-18.
3. Barry MB, Mark EC, Dick de Z, William FK, William EM, Hans-Henrik P,
Giuseppe R, Steven MS, Zhonxin Z, Shahnaz S: Effects of Losartan on
Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes
and Nephropathy. N Engl J Med 2001, 345(12):861-869.
4. Zirun W: Pathogenesis of diabetic nephropathy. Modem Journal of
Integrated Traditional Chinese and Western Medicine 2009, 18(19):2349-2350.
5. Gaofeng W, Jiancheng Y, Changmian S, Xinhong L, Jiao S, Jianmin H: Effect
of taurine on alcoholic liver disease in rats. Amino Acids 2009, 36:457-464.
6. Trachtman H, Futterweit S, Maesaka J, Ma C, Valderrama E, Fuchs A,
Tarectecan A A, Rao PS, Sturman JA, Boles TH, et al: Taurine ameliorates
chronic streptozocin-induced diabetic nephropathy in rats. Am J Physiol
1995, 269(3 Pt 2):F429-F438.
7. Erdem A, Gundogan NU, Usubutun A, Kilinc K, Erdem SR, Kara A, Bozkurt A:
The protective effect of taurine against gentamicin-induced acute
tubular necrosis in rats. Nephrol. Dial. Transplant 2000, 15(8):1175-1182.
8. Higo S, Miyata S, Jiang QY: Taurine Administration after Appearance of
Proteinuria Retards Progression of Diabetic Nephropathy in Rats. Kobe J.
Med. Sci 2008, 54(1):E35-E45.
9. Ha H, Yu MR, Kim KH: Melatonin and taurine reduce early
glomerulopathy in diabetic rats. Free Radic Biol Med 1999, 26(4):944-950.
10. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M , Vlassara H: Human and
rat mesangial cell receptors for glucose-modified proteins: potential role
in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991,
174(4):931-939.
11. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T,
Okuno Y, Morii H: Homeostasis model assessment as a clinical index of
insulin resistance in type 2 diabetic patients treated with sulfonylureas.
Diabetes care 1999, 22(5):818-822.
12. DCCT Research Group: The effect of intensive treatment of diabetes on
the development and progression of long-term complications in the
insulin-dependent diabetes mellitus. N EngI J Med 1993, 329:977-986.
13. UKPDS Group: Intensive blood-glucose control with sulphonylureas or
insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
14. Tokunaga H, Yoneda Y, Kuriyama K: Protective actions of taurine against
streptozotocin-induced hyperglycemia. Biochem Pharmacol 1979,
28(18):2807-2811.
15. Harold OG, Zak KS: Supplemental taurine in diabetic rats:effects on
plasma glucose and triglycerides. Biochem Med Metab Biol 1990, 43(1):1-9.
16. Donadio G, Fromageot P: Influence exerted by taurine on the utilization
of glucose by the rat. Bull Soc Chim Biol (Paris) 1964, 46:293-302.
Lin et al. Journal of Biomedical Science 2010, 17(Suppl 1):S46
http://www.jbiomedsci.com/content/17/S1/S46
Page 7 of 817. Kasiske BL, O’Donnel MP: The Zucker rat model of obesity, insulin
resistance, hyperlipidemia and renal injury. Hypertension 1992, 19(1
Suppl):I110-I115.
18. Lin J, Kang Y: Effect of Taurine on Experimental HyperIipidemia in Rats.
Chinese Journal of Hypertension 1998, 6(1):14-16.
19. Peng Z, Bin L, Junfeng Y, Rongzhen L, Weitao H, Fengwen L: Effect of
Natural Taurine on Reducing Blood Lipids. Acta Nutrimenta Sinica 2005,
27(1):70-71.
20. Murakami S, Yamagishi I, Asami Y, Ohta Y, Toda Y, Nara Y, Yamori Y:
Hypolipidemic Effect of Taurine in Stroke-Prone Spontaneously
Hypertensive Rats. Pharmacology 1996, 52(5):303-313.
21. Meilun X, Weifang L, Weiqiong W: The changes of the serum level of the
type IV collagen as well as laminin in diabetic nephropathies and its
correlated risk factors. HaiNan Med J 2007, 16(2):6-7.
22. Born J, Kraats AA, Bakker MAH, Assmann KJM, Heuvel LPWJ, Veerkamp JH,
Berden JHM: Selective proteinuria in diabetic nephropathy in the rat is
associated with a relative decrease in glomerular basement membrane
heparan sulphate. Diabetologia 1995, 38(2):161-172.
23. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR: Laminin –
a glycoprotein from basement membrane. The Journal of Biological
Chemistry 1979, 254(10):9933-9937.
24. Sasaki M, Yamada Y: The Laminin B2 Chain Has Multidomain Structure
Homologous to the B1 Chain. The Journal of Biological Chemistry 1987,
262(15):17111-17117.
25. Engel J, Odermatt E, Engel A, Madri JA, Furthmayr H, Rohde H, Timpl R:
Shapes, domain organizations and flexibility of laminin and fibronectin,
two multifunctional proteins of the extracellular matrix. J. Mol. Biol 1981,
150(25):97-120.
26. Paulsson M, Deutzmann R, Timpl R, Dalzoppo D, Odermatt E, Engel J:
Evidence for coiled-coil alpha-helical regions in the long arm of laminin.
EMBO J 1985, 4(2):309-316.
27. Poschl E, Schlotzer-Schrehardt U, Brachvogel B, Saito K, Ninomiya Y,
Mayer U: Collagen IV is essential for basement membrane stability but
dispensable for initiation of its assembly during early development.
Development 2004, 131(4):1619-1628.
28. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Thallas-Bonke V,
Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME,
Forbes JM: Attenuation of Extracellular Matrix Accumulation in Diabetic
Nephropathy by the Advanced Glycation End Product Cross-Link
Breaker ALT-711 via a Protein Kinase C-a−Dependent Pathway. Diabetes
2004, 53(11):2921-2930.
29. Fukui M, Nakamura T, Ebihara I, Shirato I, Tomino Y, Koide H: ECM gene
expression and its modulation by insulin in diabetic rats. Diabetes 1992,
41(12):1520-1527.
30. Yang CW, Hattori M, Vlassara H, He CJ, Carome MA, Yamato E, Elliot S,
Striker GE, Striker LJ: Overexpression of transforming growth factor-beta 1
mRNA is associated with up-regulation of glomerular tenascin and
laminin gene expression in nonobese diabetic mice. Journal of the
American Society of Nephrology 1995, 5(8):1610-1617.
doi:10.1186/1423-0127-17-S1-S46
Cite this article as: Lin et al.: Preventive effect of taurine on
experimental type II diabetic nephropathy . Journal of Biomedical Science
2010 17(Suppl 1):S46.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lin et al. Journal of Biomedical Science 2010, 17(Suppl 1):S46
http://www.jbiomedsci.com/content/17/S1/S46
Page 8 of 8